survodutide (BI 456906): the GLP-1 plus glucagon dual agonist

survodutide is an investigational 29-amino-acid acylated peptide engineered as a balanced dual agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). it is developed by Boehringer Ingelheim and supports once-weekly subcutaneous dosing. the GLP-1 arm drives appetite control and glycemic effects; the glucagon arm activates hepatic fatty-acid oxidation and FGF21 secretion. the SYNCHRONIZE-1 phase 3 trial reported about 16.6 percent mean weight loss at 76 weeks, and the Sanyal phase 2 MASH trial reported some of the strongest histologic numbers in the field.

what is survodutide?

survodutide is a 29-amino-acid peptide built on a glucagon scaffold with substitutions that tune GLP-1R potency upward and the glucagon-receptor activity to a partial-agonist level. an albumin-binding C18 fatty-diacid sidechain conjugated near the C-terminus extends the half-life to about 6 to 8 days in humans, supporting once-weekly dosing. it was originated by Zealand Pharma (ZP4915) and licensed to Boehringer Ingelheim, where it is developed as BI 456906.

glucagon agonism has been studied for decades as a partner to GLP-1. native oxyntomodulin is a 37-amino-acid proglucagon-derived peptide that acts as a dual GLP-1 receptor / glucagon receptor agonist and reduces both food intake and body weight in humans, although its short half-life makes it impractical as a drug. Day and colleagues introduced the first rationally engineered "unimolecular" dual GLP-1 plus glucagon co-agonist in 2009, and Pocai and colleagues in Diabetes the same year showed in mice that durable dual GLP-1R / GCGR agonism reverses diet-induced obesity beyond what either receptor alone achieves [1]. several earlier dual agonists (cotadutide, SAR425899, efinopegdutide, mazdutide) advanced through phase 1 to phase 2 but none has reached approval. survodutide is the most advanced Western dual GLP-1 / glucagon program as of mid-2026.

Zimmermann and colleagues (Mol Metab 2022) reported the preclinical pharmacology of BI 456906: in CHO-K1 receptor reporter assays the EC50 was about 0.33 nM at GLP-1R and 0.52 nM at GCGR, with full GLP-1R activation but partial GCGR activation at therapeutic exposure. that "GLP-1-dominant, glucagon-supplemented" tuning is a deliberate design choice to harness glucagon's catabolic benefits while limiting the hyperglycemia risk that full glucagon agonism would create.

how does it work?

survodutide engages two receptors. the GLP-1 receptor arm drives glucose-dependent insulin secretion, gastric-emptying delay, and central appetite suppression via hypothalamic POMC/CART neurons and brainstem AP/NTS circuits. the glucagon receptor arm, mostly liver-dominant, raises hepatic cAMP, increases fatty-acid oxidation, ketogenesis, mitochondrial biogenesis, and FGF21 secretion. FGF21 then feeds back centrally via the KLB / FGFR1c complex to support weight loss.

the GLP-1 receptor arm is the same machinery that semaglutide and liraglutide engage. survodutide drives insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon during hyperglycemia (a separate effect from the agonism the molecule provides at the same receptor in alpha cells), slows gastric emptying, and activates central satiety circuits. the GLP-1 arm is responsible for most of the appetite suppression, glycemic control, and gastrointestinal side-effect profile.

the glucagon receptor arm is what makes survodutide distinct from semaglutide or tirzepatide. liver-dominant GCGR activation raises hepatic cAMP through the same cAMP-PKA pathway that acute glucagon uses to mobilize glycogen, but chronic engagement shifts the liver toward fatty-acid oxidation, ketogenesis, mitochondrial biogenesis, and lipolysis of intrahepatic triglyceride stores. hepatic FGF21 secretion is induced, and FGF21 acts centrally via the KLB / FGFR1c complex in the hypothalamus to support weight loss [2]. mice lacking liver Fgf21 are partially resistant to GCGR-mediated weight loss, anchoring FGF21 as a key downstream mediator. the glucagon arm also increases resting energy expenditure and stimulates amino-acid catabolism (which is why plasma amino acids drop with GCGR agonism, a useful pharmacodynamic marker of target engagement).

the partial GCGR activation is not a weakness, it is a feature. hepatocytes have high receptor reserve, so a partial agonist can deliver near-maximal cAMP signaling at saturating drug concentrations, sufficient to drive fatty-acid oxidation and FGF21 induction without driving the full gluconeogenic activation that would worsen glycemia. that tuning is the recurring design rationale across the GLP-1 / glucagon dual-agonist class.

what does the evidence show?

SYNCHRONIZE-1 phase 3 (April 2026 topline): about 16.6 percent mean body-weight reduction versus 3.2 percent placebo at 76 weeks; up to 85.1 percent achieving 5 percent or greater weight loss. the Sanyal NEJM 2024 phase 2 MASH trial reported 47 to 62 percent histologic MASH improvement without fibrosis worsening versus 14 percent placebo, and 34 to 36 percent fibrosis improvement of one stage or greater versus 22 percent placebo. phase 2 in T2D (Bluher 2024) showed dose-dependent HbA1c and weight reductions.

the marquee phase 2 obesity trial (le Roux et al., Lancet Diabetes Endocrinol 2024) enrolled 387 adults with BMI 27 or greater without diabetes and tested weekly survodutide 0.6, 2.4, 3.6, or 4.8 mg over 46 weeks (20 weeks of titration plus 26 weeks of maintenance) [3]. the 4.8 mg arm produced about 18.7 percent placebo-corrected weight loss, with 82.8 percent achieving 5 percent or greater loss compared with 25.9 percent on placebo. GI adverse events were dose-dependent and led to discontinuation in roughly 20 to 25 percent at the top doses. the SYNCHRONIZE-1 phase 3 topline announced on 2026-04-28 confirmed efficacy at 76 weeks: the co-primary endpoints were met, with up to 16.6 percent mean body-weight reduction in the efficacy estimand versus 3.2 percent placebo, and cardiometabolic secondary endpoints (waist circumference, blood pressure, lipids) all favoring survodutide. the rest of the SYNCHRONIZE family (SYNCHRONIZE-2 in obesity plus T2D, SYNCHRONIZE-3 in weight maintenance, SYNCHRONIZE-CVOT in roughly 10,000 adults with high cardiovascular risk) is still in-flight as of mid-2026.

the MASH dataset is the standout differentiator. Sanyal and colleagues (NEJM 2024) randomized 295 adults with biopsy-confirmed MASH and F1 to F3 fibrosis to weekly survodutide 2.4, 4.8, or 6.0 mg or placebo for 48 weeks. histologic MASH improvement without fibrosis worsening occurred in 47 to 62 percent of survodutide arms versus 14 percent on placebo, fibrosis improvement of one stage or greater occurred in 34 to 36 percent versus 22 percent, and MRI-PDFF liver-fat reduction of 30 percent or greater occurred in 64 to 67 percent versus 14 percent [4]. for context, resmetirom (the first FDA-approved MASH agent) achieved MASH resolution in 26 to 30 percent in MAESTRO-NASH. survodutide's phase 2 numbers are some of the strongest histologic numbers from a non-thyromimetic agent.

the T2D dataset (Bluher et al., Diabetologia 2024) randomized 411 adults with T2D and HbA1c 7.0 to 10.0 percent to weekly survodutide up-titrated to 0.9, 1.8, or 2.7 mg versus placebo and open-label semaglutide 1.0 mg over 16 weeks. survodutide produced dose-dependent HbA1c reductions of up to about 1.8 percent and weight reductions exceeding semaglutide 1.0 mg in head-to-head observation, although the comparison is open-label and short. a phase 1 cirrhosis PK study by Lawitz and colleagues (J Hepatol 2024) showed that hepatic impairment (Child-Pugh A through C) did not require survodutide dose adjustment, with safety acceptable and the expected GI adverse-event predominance.

FDA and regulatory status

survodutide is not FDA-approved for any indication. Boehringer Ingelheim has guided that an NDA submission for obesity will follow phase 3 program completion (likely late 2026 / 2027). survodutide is not on the FDA Drug Shortage List, so 503A and 503B compounding pathways do not apply. "research-grade survodutide" sold by gray-market vendors is regulatory-noncompliant and has no validated identity, purity, or sterility guarantees.

the cardiovascular outcomes question is open. SYNCHRONIZE-CVOT is the dedicated large outcomes trial in roughly 10,000 adults with obesity plus established cardiovascular disease, CKD, or substantial risk factors, with readout expected in 2027 or later. the cardiovascular bar for new obesity drugs is set by SELECT (semaglutide showed a 20 percent MACE reduction), and any new obesity drug seeking a CV indication will need to clear at least non-inferiority on that background. the glucagon-arm theoretical concerns (heart rate, hepatic glucose output) make a clean CVOT a non-negotiable for full survodutide label expansion.

GLP-1 receptor agonists (which would include survodutide's GLP-1 arm) are on the WADA 2026 monitoring program rather than the fully prohibited list, with classification within the S4 Hormone and Metabolic Modulators category an active area of policy attention. athletes in tested sports should treat survodutide as ethically and competitively high-risk pending WADA's next update.

safety profile and side effects

gastrointestinal events dominate and resemble the GLP-1 class: nausea, vomiting, diarrhea, constipation, decreased appetite, dyspepsia. GI-related discontinuation at the top tested doses was around 20 to 25 percent in the le Roux phase 2 obesity trial. the glucagon arm raises theoretical concerns about hepatic glucose output, lean-mass loss, and heart rate, but published trial data do not show alarming signals.

the GI profile resembles GLP-1 class with slightly higher GI-discontinuation rates than semaglutide at comparable weight-loss percentages, consistent with the added glucagon arm modestly amplifying GI signaling. titration over 16 to 24 weeks is the standard mitigation, mirroring semaglutide and tirzepatide. counseling priorities are small frequent low-fat meals, avoidance of triggers (alcohol, very fatty meals), aggressive hydration, judicious antiemetics for breakthrough nausea, and patience through the 4 to 6 week post-titration window where GI events peak then recede.

cardiovascular signals are small. heart rate increases by 2 to 5 bpm, the same range as semaglutide and tirzepatide, and blood pressure reductions are favorable. small ALT elevations are possible, but net effect on liver biochemistry in MASH is favorable. dehydration-mediated AKI is the dominant renal risk. gallbladder disease is the class-typical concern at higher rates of rapid weight loss. transient elevations in lipase and amylase occur at incidences typical for the incretin class, mostly asymptomatic. the rodent thyroid C-cell tumor finding for the GLP-1 class persists in labeling for the entire incretin field; no clear human signal has emerged. long-term safety beyond about 2 years has not been characterized. cardiovascular outcomes await SYNCHRONIZE-CVOT. special-population data (pediatric, pregnancy, severe renal) are not yet published.

where it fits in peptide therapy

survodutide sits in the GLP-1 plus glucagon dual-agonist family. its closest mechanistic siblings are cotadutide, mazdutide, and efinopegdutide. its closest single-agonist comparators are semaglutide (GLP-1 mono) and tirzepatide (GIP plus GLP-1). its triple-agonist successor is retatrutide. survodutide's distinct value proposition is the glucagon arm, which adds energy expenditure and direct hepatic lipid oxidation that GIP and pure GLP-1 do not provide.

the comparison to semaglutide is the cleanest entry point. semaglutide STEP-1 produced about 14.9 percent weight loss at 68 weeks; survodutide SYNCHRONIZE-1 produced about 16.6 percent at 76 weeks. no direct head-to-head obesity trial exists. semaglutide has approved cardiovascular benefit (SELECT) and a MASH accelerated approval; survodutide has neither yet. the comparison to tirzepatide sets the mechanistic frame differently. tirzepatide SURMOUNT-1 produced about 22.5 percent weight loss at 72 weeks at the 15 mg dose; survodutide is in a lower band on raw weight loss. but the mechanistic comparison is GIP-mediated adipocyte lipid buffering and insulinotropic synergy versus glucagon-driven energy expenditure and hepatic lipid oxidation: different levers, not better or worse.

the cousin molecules add useful context. liraglutide is the daily GLP-1 mono-agonist that established the modern incretin era. cagrilintide paired with semaglutide as CagriSema is the investigational long-acting amylin combination. native oxyntomodulin is the conceptual ancestor of survodutide. for foundational biology on the incretin and proglucagon families, our free peptides and your body module covers the underlying physiology, and the comparison set continues to evolve as the GLP-1, GIP, glucagon, and amylin axes get combined in new ways.